Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRII - Cell Robotics International, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (242)	2/28/2000 10:14:00 AM
From: sheetmillgalvanize	Read Replies (1) \| Respond to of 252

Monday February 28, 7:59 am Eastern Time Company Press Release Cell Robotics Announces Successful Completion of Private Placement Funds Used to Ramp Up Production, Marketing and Sales of The Only FDA-approved Laser Device (Personal Lasette(R)) Used by Diabetics to Draw Blood for Glucose Testing ALBUQUERQUE, N.M.--(BW HealthWire)--Feb. 28, 2000-- Cell Robotics International (OTCBB:CRII - news), a research and medical laser device company, today announced that on February 25 it successfully completed a non-brokered, $1,080,000 private placement using 450,000 shares of its common stock. On February 18, the company reached agreement on a term sheet, to sell the shares of restricted common stock at an approximate 30 percent discount to the market price. Terms of the private placement allow the purchase of an additional 50,000 shares of common stock under the same terms over the course of the next eight weeks. The company raised this money exclusively through its own efforts and without the use of a placement agent. Additionally, terms call for appointment of the investor to the current Board of Directors and to be nominated to the Board of Directors for vote by the shareholders at the annual meeting in May 2000. The investor is an experienced international technologist and manager who is the president of his own engineering company. The proceeds from this private placement will be used primarily for the manufacturing, sales and marketing efforts of the company's proprietary, leading-edge laser device, the Personal Lasette. The Personal Lasette is the only FDA-cleared alternative to the needle or steel blade lancet currently available for diabetics to draw blood to test their glucose levels for subsequent insulin injections. The Personal Lasette causes little pain, reduces finger soreness and eliminates the fear of sticking a steel lancet into one's finger. Cell Robotics' President and Chief Executive Officer Dr. Ronald Lohrding commented, ``We are pleased to obtain additional equity capital at this time. The proceeds from this placement will allow us to accelerate our manufacturing, marketing and sales efforts of the company's Personal Lasette. ``Moreover, we are excited to be able to ramp up marketing of the Personal Lasette to diabetics first in the United States and then as our production capability increases, to the more than 110 million diabetics worldwide.' Dr. Lohrding added, ``The company plans to utilize proven marketing techniques to drive sales through traditional channels such as direct-mail, tradeshows, print publications aimed at diabetics, catalogs, the Internet, pharmacies and distributors.' About Cell Robotics International Cell Robotics International (www.cellrobotics.com) is a medical products company committed to enhancing the quality of life through technology. CRII manufactures, markets and distributes the Lasette, the only FDA-cleared alternative to the needle or steel blade lancet currently available for diabetics to draw blood so as to test their glucose levels. The company's additional products include its IVF Workstation(TM), a state-of-the-art infertility treatment, and the Cell Robotics Workstation(TM), an innovative scientific research instrument that uses laser light to transform a microscope from a viewing device into a tool for physically manipulating and dissecting living cells in microspace. Forward-looking statements (statements which are not historical fact) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including the following: changes in economic conditions, general competitive factors, the company's ability to execute its manufacturing, service and product sales plans and uncertainties detailed in the company's filings with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Contact: Cell Robotics International Inc., Albuquerque Craig T. Rogers, 719/590-1793 investor-info@cellrobotics.com or Coffin Communications Group Sean Collins / Patrick Denny, 818/789-0100 Fax 818/789-1152 www.coffincg.com -------------------------------------------------------------------------------- More Quotes and News: Cell Robotics International Inc (OTC BB:CRII.OB - news) Related News Categories: biotech, health care, medical/pharmaceutical -------------------------------------------------------------------------------- Help -------------------------------------------------------------------------------- Copyright ¸ 2000 Yahoo! All Rights Reserved. Privacy Policy - Terms of Service Copyright 2000 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database, redistributing via a computer network or in a printed form. Questions or Comments?